Merck & Co., Inc.

Latest by Merck & Co., Inc.

Promo Image

Merck Announces Expanded Co-Pay Assistance Program for Isentress (Raltegravir)

Whitehouse Station, N.J. -- Merck today announced an enhanced co-pay assistance program for people living with HIV-1 who are taking the Company's first-in-class HIV-1 integrase inhibitor, ISENTRESS® (raltegravir) Tablets. The program provides importa...

Promo Image

Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options

Toronto -- A worldwide expanded access program for HIV/AIDS patients with limited or no treatment options was announced today by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., with respect to its investigational HIV integrase inhibitor, MK-0518...